American journal of veterinary research · 1998
Skeletal muscle glycolytic capacity and phosphofructokinase regulation in horses with polysaccharide storage myopathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Valberg S J, Townsend D, Mickelson J R
Аннотация
OBJECTIVE: To determine whether polysaccharide storage myopathy (PSSM) in Quarter Horses is attributable to a defect in glycolysis or in the allosteric regulation of phosphofructokinase (PFK) enzyme.
ANIMALS: Muscle biopsy specimens were obtained from 6 Quarter Horses with PSSM and 8 Quarter Horse or Thoroughbred control horses.
PROCEDURES: Maximal activity of glycogenolytic and glycolytic enzymes was determined spectrophotometrically. Maximal activity of PFK was determined for each horse at pH 8.0, and at pH 7.0 when variable concentrations of the activators, fructose 6 phosphate, fructose 2,6 bisphosphate, and adenosine monophosphate or inhibitors adenosine triphosphate and citrate were added to the reaction mixture. Relative activity was calculated as activity at pH 7/maximal PFK activity.
RESULTS: Deficiencies in glycogenolytic or glycolytic enzyme activities were not evident in horses with PSSM. Differences between horses with PSSM and control horses in relative activity of PFK were not apparent for any of the activators or inhibitors used in the study.
CONCLUSIONS: In a group of horses with PSSM, we were unable to detect a glycogenolytic or glycolytic enzyme deficiency or abnormality in the allosteric regulation of PFK.
CLINICAL RELEVANCE: Although PSSM is clinically and histologically similar to glycogenolytic/glycolytic enzyme deficiencies in human beings and other animal species, abnormalities in this metabolic pathway are not present in horses with PSSM.
ANIMALS: Muscle biopsy specimens were obtained from 6 Quarter Horses with PSSM and 8 Quarter Horse or Thoroughbred control horses.
PROCEDURES: Maximal activity of glycogenolytic and glycolytic enzymes was determined spectrophotometrically. Maximal activity of PFK was determined for each horse at pH 8.0, and at pH 7.0 when variable concentrations of the activators, fructose 6 phosphate, fructose 2,6 bisphosphate, and adenosine monophosphate or inhibitors adenosine triphosphate and citrate were added to the reaction mixture. Relative activity was calculated as activity at pH 7/maximal PFK activity.
RESULTS: Deficiencies in glycogenolytic or glycolytic enzyme activities were not evident in horses with PSSM. Differences between horses with PSSM and control horses in relative activity of PFK were not apparent for any of the activators or inhibitors used in the study.
CONCLUSIONS: In a group of horses with PSSM, we were unable to detect a glycogenolytic or glycolytic enzyme deficiency or abnormality in the allosteric regulation of PFK.
CLINICAL RELEVANCE: Although PSSM is clinically and histologically similar to glycogenolytic/glycolytic enzyme deficiencies in human beings and other animal species, abnormalities in this metabolic pathway are not present in horses with PSSM.